The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
- ByBenzinga-
Biotech stocks rebounded in the week ended July 23, thanks to ...Full story available on Benzinga.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ
Symbol | Exchange | Currency |
|---|
122.20
+1.78(+1.48%)
- Volume:61,605
- Bid/Ask:121.80/122.32
- Day's Range:120.51 - 122.20
LGND Overview
- Prev. Close
- 120.42
- Day's Range
- 120.51-122.2
- Revenue
- 208.41M
- Open
- 120.4
- 52 wk Range
- 78.26-219.73
- EPS
- 2.31
- Volume
- 61,605
- Market Cap
- 2.02B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 150,856
- P/E Ratio
- 52.03
- Beta
- 1.15
- 1-Year Change
- -3.03%
- Shares Outstanding
- 16,652,080
- Next Earnings Date
- Jul 29, 2021
What is your sentiment on Ligand Pharmaceuticals Incorporated?
or
Vote to see community's results!
Ligand Pharmaceuticals Incorporated News
- H.C. Wainwright Stick to Their Buy Rating for Ligand Pharma
- ByInvesting.com-
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (NASDAQ:LGND) on Monday, setting a price target of $310, which is approximately 173.90% above the...
- Ligand Pharmaceuticals adds Jennifer Cochran to its board of directors
- BySeeking Alpha-
Ligand Pharmaceuticals (LGND) announces the appointment of Jennifer Cochran to the company's board of directors.Cochran is the Shriram Chair of the Department of Bioengineering...
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Neutral | Sell | Neutral |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Sell | Sell |
| Summary | Strong Buy | Strong Buy | Buy | Sell | Neutral |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,734.60 | 2,765.00 | 2,706.70 | +96.6 | +3.66% | 3.51M | NASDAQ | |||
| 373.40 | 377.54 | 367.00 | +5.59 | +1.52% | 15.50M | NASDAQ | |||
| 154.98 | 162.91 | 153.55 | -12.62 | -7.53% | 197.51K | NYSE | |||
| 88.52 | 90.00 | 84.67 | -2.80 | -3.07% | 1.72M | NASDAQ | |||
| 195.32 | 196.40 | 189.76 | +9.25 | +4.97% | 26.90M | NYSE | |||
| 53.16 | 53.92 | 52.94 | -0.02 | -0.04% | 18.19M | NASDAQ | |||
| 195.07 | 196.46 | 189.95 | +2.99 | +1.56% | 14.61M | NASDAQ | |||
| 43.59 | 43.74 | 42.26 | +1.49 | +3.54% | 36.77M | NYSE | |||
| 301.20 | 302.39 | 296.98 | +0.72 | +0.24% | 3.69M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 21.11 | 21.25 | 20.91 | +0.12 | +0.57% | 7.10M | NYSE | |||
| 61.14 | 61.55 | 60.43 | -0.02 | -0.03% | 664.16K | NYSE | |||
| 38.89 | 39.55 | 36.08 | +0.88 | +2.32% | 60.84M | NYSE | |||
| 20.39 | 20.65 | 20.16 | +0.03 | +0.12% | 5.25M | NYSE | |||
| 15.91 | 16.32 | 14.02 | +3.18 | +24.98% | 98.72M | NASDAQ |
Ligand Pharmaceuticals Incorporated Company Profile
Ligand Pharmaceuticals Incorporated Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company’s commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company’s partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Read More
- 2021-07-26 06:29:59Earnings today.
- 2021-02-22 14:19:48
this could be another short squeeze - 2021-02-18 20:17:57
Just bought - 2021-02-04 22:43:27let wall street bets know about this
- 2021-02-04 16:54:25easy 300, high growth profitable company with lots of shorties to squeeze
- 2021-02-04 09:46:15short squeeze, after the good earning result?
- 2021-01-24 08:29:22short squeeze?
- 2019-06-17 18:50:59Buy now
- 2019-05-03 15:08:17What in the world
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.